1 - 25 (out of 46)
Cyclosporine in Takotsubo syndrome (CIT-DZHK29)
In the DZHK-funded CIT-DZHK29 study, researchers from Heidelberg are investigating for the first time whether an anti-inflammatory drug can alleviate myocardial damage in broken heart syndrome.
| Recruiting status | Recruiting planned |
|---|---|
| Principal Investigators | Principal investigator: Norbert Frey (Heidelberg), Co-PI: Bastian Bruns (Heidelberg) |
A first-in-human feasibility study to evaluate the safety (and short term effectiveness) of the autologous GrOwnValve transcatheter pulmonary heart valve (GECT-DZHK28)
In the GECT-DZHK28 study of the German Center for Cardiovascular Research, scientists are testing a heart valve replacement made of the patient's own tissue in humans, which is unique worldwide according to the current state of knowledge.
| Recruiting status | Recruiting ongoing |
|---|---|
| Principal Investigators | Principal investigator: Boris Schmitt (Berlin) |
CAtheter-Based Ablation of atrial fibrillation compared to conventional treatment in patients with Heart Failure with Preserved Ejection Fraction (CABA-HFPEF-DZHK27)
CABA-HFPEF-DZHK27 is a large, multicenter study investigating whether catheter ablation achieves better results than drug treatment in heart failure patients with atrial fibrillation.
| Recruiting status | Recruiting ongoing |
|---|---|
| Principal Investigators | Principal investigator: Abdul S. Parwani (Berlin), Co-PI: Paulus Kirchhof (Hamburg), Stefan Kääb (München), Roland R Tilz (Lübeck), Tim Friede (Göttingen), Burkert Pieske |
A multicenter, randomized, double-blind, placebo-controlled trial evaluating immunosuppressive treatment in patients with chronic virus-negative inflammatory cardiomyopathy (TRINITY-DZHK26)
The multicenter, randomized, double-blind, placebo-controlled TRINITY-DZHK26 trial is testing the success of immunosuppressive treatment in patients with chronic virus-negative inflammatory cardiomyopathy.
| Recruiting status | Recruiting ongoing |
|---|---|
| Principal Investigators | Principal investigator: Ulrich Grabmaier (München), Co-PI: Steffen Massberg (München) |
Tricuspid Intervention in Heart Failure (TRICI-HF-DZHK24)
The DZHK study TRICI-HF-DZHK24 is investigating whether patients with a leaking tricuspid valve benefit from a catheter-assisted repair of the heart valve.
| Recruiting status | Recruiting ongoing |
|---|---|
| Principal Investigators | Principal investigator: Jörg Hausleiter (München), Co-PI: Thomas Stocker, Daniel Braun, Steffen Massberg (München) |
Effect of anti-fibrotic therapy on regression of myocardial fibrosis after transcatheter aortic valve implantation (TAVI) in aortic stenosis patients with high fibrotic burden (Reduce-MFA-DZHK25)
The REDUCE-MFA-DZHK25 trial is testing whether antifibrotic drugs can reduce cardiac scarring after TAVI and improve patient prognosis.
| Recruiting status | Recruiting ongoing |
|---|---|
| Principal Investigators | Principal investigator: Miriam Puls (Göttingen), Co-PI: Elisabeth Zeisberg (Göttingen) |
Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for >60 Year-olds (PRIMARY)
The PRIMARY study investigates whether a surgical or catheter-based approach is better for repairing mitral valve prolapse.
| Recruiting status | Recruiting ongoing |
|---|---|
| Principal Investigators | Principal investigator for Germany: Volkmar Falk (Berlin), PI (Sponsor): Annetine C. Gelijns (Icahn School of Medicine at Mount Sinai, NY, USA), Co-PI for Germany: Stefan Blankenberg (Hamburg), Michael Borger (Leipzig) |
Munich Remote SpO2 and Heart Rate Assessment in Covid-19 patients (COVID SMART vormals MR SPOC)
In the COVID SMART trial, modern smartwatches continuously measure ECG, pulse, and oxygen saturation in the blood of COVID-19 patients and transfer these data into the hospital to get treatment advice.
| Recruiting status | Study completed |
|---|---|
| Principal Investigators | Principal investigator: Moritz Sinner (München) |
Stopping ACE-inhibitors in COVID-19 (ACEI-COVID-19)
The study investigates the effects on the course of COVID-19 disease when ACE inhibitors are paused or replaced by antihypertensives with a different mechanism of action in COVID-19 patients.
| Recruiting status | Study completed |
|---|---|
| Principal Investigators | Principal investigator: Steffen Massberg (München), Co-PI: Konstantinos Rizas (München) |
Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT)
The Germany-wide COVIDPREVENT trial is investigating whether the administration of the blood thinner Rivaroxaban can reduce thrombotic events such as heart attack, pulmonary embolism or stroke in CoVID-19 patients.
| Recruiting status | Study completed |
|---|---|
| Principal Investigators | Principal investigator: Ulf Landmesser (Berlin) |
Cardiac Magnetic Resonance guidance of Implantable Cardioverter Defibrillator implantation in non-ischaemic dilated cardiomyopathy (CMR-ICD-DZHK23)
The CMR-ICD-DZHK23 study wants to optimise the implantation of a defibrillator in patients with non-ischemic cardiomyopathy based on
fibrosis on cardiac MRI.
| Recruiting status | Recruiting ongoing |
|---|---|
| Principal Investigators | Principal investigator: Ingo Eitel (Lübeck) |
First prospective randomized trial to examine a differential therapeutic response in symptomatic patients with non-obstructive coronary artery disease after coronary physiological testing (EXAMINE-CAD-DZHK22)
The EXAMINE-CAD-DZHK22 study is investigating which drugs help with circulatory disorders of small heart vessels.
| Recruiting status | Recruiting permanently stopped, after recruiting started |
|---|---|
| Principal Investigators | Principal investigator: Ulf Landmesser (Berlin), Co-PI: Barbara Stähli (Berlin) |
TranslatiOnal Registry for CardiomyopatHies-Plus (TORCH-Plus-DZHK21)
TORCH-Plus is a large-scale prospective data & biospecimen repository of patients with non-ischemic cardiomyopathies.
| Recruiting status | Recruiting ongoing |
|---|---|
| Principal Investigators | Principal investigator: Benjamin Meder (Heidelberg) |
Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure (BioVAT-DZHK20)
BioVAT-HF-DZHK20 trial is investigating under which conditions engineered human myocardium is safe to use in the treatment of patients with end-stage heart failure.
| Recruiting status | Recruiting ongoing |
|---|---|
| Principal Investigators | Principal investigator: Wolfram-Hubertus Zimmermann (Göttingen) |
Prediction of Acute Coronary Syndrome in Acute Ischemic Stroke (PRAISE-DZHK19 I DZNEB001)
The aim of the study PRAISE-DZHK19 I DZNEB001 is to establish a clinical algorithm that enables the prediction of acute coronary syndrome or heart attack in stroke patients.
| Recruiting status | Study completed |
|---|---|
| Principal Investigators | Principal investigator: Matthias Endres (Berlin), Co-PI: Ulf Landmesser, Christian Nolte (Berlin) |
Effect of Metformin in insulin resistant patients with heart failure with reduced ejection fraction (METRIS-HF-DZHK18)
The METRIS-HF-DZHK18 trial aims to find out whether improved energy metabolism can increase heart efficiency in patients with cardiac insufficiency.
| Recruiting status | Recruiting complete, follow-up complete |
|---|---|
| Principal Investigators | Principal Investigator: Wolfram Döhner (Berlin), Co-PI: Burkert Pieske, Tim Friede (Göttingen) |
Home-Based Screening for Early Detection of Atrial Fibrillation in Primary Care Patients Aged 75 Years and Older (SCREEN AF-DZHK15)
The SCREEN-AF study aims to improve the early detection of atrial fibrillation using a new “rhythm patch” with an integrated ECG recording unit which is applied to the patient’s chest.
| Recruiting status | Study completed |
|---|---|
| Principal Investigators | Principal investigator for Germany: Rolf Wachter (Göttingen und Leipzig), Co-PI: Eva Hummers (Göttingen), Jeff Healey, David Gladstone (Canadian Stroke Prevention Intervention Network, Kanada) |
Evaluating the benefit of concurrent tricuspid valve repair during mitral surgery (CTSN-TVR-DZHK14)
The aim of the study is to clarify whether it is beneficial to operate the tricuspid valve in the right heart at the same time if the mitral valve is defective, even if the right heart valve is not yet very leaky.
| Recruiting status | Recruiting complete, follow-up complete |
|---|---|
| Principal Investigators | Principal investigator for Germany: Volkmar Falk (Berlin), PI (Sponsor): Annetine C. Gelijns (Icahn School of Medicine at Mount Sinai, NY, USA) |
Validation of Cardiovascular Magnetic Resonance against Invasive Haemodynamics in Patients with Heart Failure with Preserved Ejection Fraction (Decipher HFpEF-DZHK12)
The DECIPHER HFpEF-DZHK12 study investigates whether diastolic heart failure can be better diagnosed and its causes clarified with the help of cardiovascular magnetic resonance imaging (CMR).
| Recruiting status | Recruiting complete |
|---|---|
| Principal Investigators | Principal investigator: Eike Nagel (Frankfurt) |
Exercise Training in Patients with Left Ventricular Assist Device (Ex-VAD-DZHK11)
This study is examining whether a tailored physical exercise can improve the fitness and quality of life of patients with an artificial heart.
| Recruiting status | Study completed |
|---|---|
| Principal Investigators | Principal investigator: Frank Edelmann (Berlin), Co-PI: Burkert Pieske, Martin Halle (München), Volkmar Falk (Berlin) |
Randomized Trial of TAVI versus SAVR in Patients with Symptomatic Severe Aortic Valve Stenosis and Intermediate Risk of Mortality (DEDICATE-DZHK6)
The DEDICATE-DZHK6 study is investigating whether surgical or transcatheter aortic valve implantation is the superior long-term treatment option for patients with severe aortic valve stenosis.
| Recruiting status | Recruiting complete, follow-up continuing |
|---|---|
| Principal Investigators | Principal investigator: Stefan Blankenberg (Hamburg), Co-PI: Moritz Seiffert (Hamburg) |
Ultrasound evaluation of the inferior vena cava in addition to clinical assessment to guide decongestion in acute decompensated heart failure: a pilot study (CAVA-ADHF-DZHK10)
This trial is examining whether an ultrasound evaluation of the inferior vena cava in acute decompensated heart failure (ADHF) with congestion can be implemented in hospitals’ everyday routine in a large number of patients.
| Recruiting status | Study completed |
|---|---|
| Principal Investigators | Principal investigator: Alexander Jobs (Lübeck), Co-PI: Holger Thiele (Leipzig) |
Cardiovascular magnetic resonance real time exercise stress testing in heart failure with preserved ejection fraction (HFpEF-stress-DZHK17)
Researchers will test in this trial whether the newly developed real-time CMR technology is suitable for the early and safe diagnosis of HFpEF.
| Recruiting status | Study completed |
|---|---|
| Principal Investigators | Principal investigator: Andreas Schuster (Göttingen) |
Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy (CLOSURE-AF-DZHK16)
The DZHK study CLOSURE-AF compares the benefit of the left atrial appendage closure with the best possible drug therapy for high-risk patients with atrial fibrillation.
| Recruiting status | Recruiting complete, follow-up continuing |
|---|---|
| Principal Investigators | Principal investigator: Ulf Landmesser (Berlin), Co-PI: Ingo Eitel (Lübeck), Leif-Hendrik Boldt (Berlin) |
SPIRonolactone In the Treatment for Heart Failure (SPIRIT-HF-DZHK8)
The SPIRIT-HF-DZHK8 study investigates whether the drug spironolactone can reduce the number of people with preserved ejection fraction who end up in hospital and the number of people who die from heart failure.
| Recruiting status | Recruiting complete, follow-up continuing |
|---|---|
| Principal Investigators | Principal investigator: Frank Edelmann (Berlin) (vormals Burkert Pieske) |